| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3405729 | Journal of Global Antimicrobial Resistance | 2014 | 4 Pages |
Abstract
Vancomycin-resistant enterococci (VRE) have emerged as a major nosocomial pathogen. Alternatives for the treatment of infection with VRE include linezolid and daptomycin. Experience with these agents, especially daptomycin, is limited in India. The minimum inhibitory concentration of linezolid and daptomycin against 98 clinical isolates of VRE was tested by E-test. Daptomycin and linezolid showed good activity, with susceptibility rates of 93.9% and 96.9%, respectively.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Shakti Laishram, Rani D. Sahni, Shalini Anandan, Veeraragavan Balaji,